Key Highlights

  • Stockholders representing 13,493,572 shares, roughly 69% of voting power, approved a general assignment of assets to Vicarious Liquidation, LLC.
  • The chief executive officer, president and chief technology officer will receive severance payments of $672,699, $779,190 and $611,261 respectively.
  • During a specially convened meeting, the board determined that assigning virtually all assets to Vicarious Liquidation, LLC was in the best interests of creditors.

Vicarious Surgical Inc. (OTC: RBOT) obtained shareholder backing to transfer virtually all of its assets to a creditor‑controlled trust, with holders of 13,493,572 shares, about 69% of the voting pool, signing off on the plan. The move represents the company’s fourth material‑agreement filing of the year and paves the way for a formal corporate wind‑down. Executives will exit under pre‑negotiated severance terms, signaling a clean break from operational leadership.

Asset Transfer Approved

During a specially convened meeting, the board determined that assigning virtually all assets to Vicarious Liquidation, LLC was in the best interests of creditors. The assignee is empowered to act as attorney‑in‑fact, sell or otherwise dispose of assets, and apply proceeds to satisfy creditor claims. This structure positions creditors ahead of shareholders, who will receive any residual only after all liabilities are settled.

Executive Exit Packages

Simultaneous with the asset transfer, the board accepted the resignations of its directors and terminated the employment of the chief executive officer, the president and the chief technology officer effective at the close of business. Under their employment contracts, the chief executive officer will receive a severance of $672,699, the president $779,190 and the chief technology officer $611,261, each with full vesting of outstanding equity awards. These cash outlays are contractual obligations and will be drawn from the Assignment Estate, reducing the pool available for creditor recovery.

The departures clear the way for a streamlined liquidation process without managerial friction.

Market Reaction and Shareholder Sentiment

Following the announcement, the company’s stock experienced a sharp decline, reflecting heightened investor pessimism about the prospects for recovery. Trading activity underscored the market’s focus on the liquidation roadmap rather than short‑term price movements. Peer movements in the broader medical‑device and biotech sectors provided context, with some peers seeing modest gains while others faced further declines.

The clarity of the liquidation plan may temper future volatility as stakeholders adjust to the new reality.

Next Steps and Timeline

The board also resolved to deregister the company’s common stock under the 1934 Exchange Act by filing the appropriate form, a step that will become effective after the statutory waiting period. A Certificate of Dissolution will be filed with the Delaware Secretary of State shortly thereafter, completing the corporate winding‑up. Creditors will gauge the speed of asset sales, while shareholders await any residual distribution.

The upcoming filing serves as a concrete catalyst for finalizing the liquidation and ending ongoing reporting obligations. The company’s principal office remains at 78 Fourth Avenue, Waltham, Massachusetts 02451. Based on the Form 8‑K filed in recent days.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.